Skip to main content

Advertisement

SpringerLink
Log in

Immunologic monitoring in chronic lymphocytic leukemia

  • Published:
Current Oncology Reports Aims and scope Submit manuscript

Abstract

Chronic lymphocytic leukemia (CLL) is characterized by progressive defects in humoral- and cell-mediated immunity. These defects are manifested as a propensity to develop infections with encapsulated bacteria, and less frequently, with gram-negative enterics. In addition, reactivation of viruses such as herpesvirus is not uncommon. Treatment of the disease further exacerbates immunosuppression by depleting immune effectors and broadening the spectrum of potentially offending pathogens. Risk of infection can potentially be reduced by administration of intravenous immunoglobulin and use of prophylactic antibiotics for individuals who are at high risk. Current work focuses on development of cellular and cytokine therapy to facilitate immune reconstitution in patients with CLL, thereby reducing morbidity and mortality and potentially improving survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Hamblin TJ, Oscier DG, Young BJ: Autoimmunity in chronic lymphocytic leukaemia. J Clin Pathol 1986, 39:713–716.

    PubMed  CAS  Google Scholar 

  2. Morra E, Nosari A, Montillo M: Infectious complications in chronic lymphocytic leukaemia. Hematol Cell Ther 1999, 41:145–151.

    Article  PubMed  CAS  Google Scholar 

  3. Tsiodras S, Samonis G, Keating MJ, Kontoyiannis DP: Infection and immunity in chronic lymphocytic leukemia. Mayo Clin Proc 2000, 75:1039–1054.

    PubMed  CAS  Google Scholar 

  4. Wijermans PW, Gerrits WB, Haak HL: Severe immunodeficiency in patients treated with fludarabine monophosphate. Eur J Haematol 1993, 50:292–296.

    Article  PubMed  CAS  Google Scholar 

  5. Anaissie EJ, Kontoyiannis DP, O’Brien S, et al.: Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med 1998, 129:559–566. A thorough report of infections seen in previously treated patients receiving fludarabine. The authors include the risk factors for developing infection, incidence, types of organisms, and recommendations for prophylactic antibiotics.

    PubMed  CAS  Google Scholar 

  6. Keating MJ, O’Brien S, Lerner S, et al.: Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 1998, 92:1165–1171.

    PubMed  CAS  Google Scholar 

  7. Block JB, Haynes HA, Thompson WL, Neiman PE: Delayed hypersensitivity in chronic lymphocytic leukemia. J Natl Cancer Inst 1969, 42:973–980.

    PubMed  CAS  Google Scholar 

  8. Levi F, Randimbison L, Te VC, La Vecchia C: Non-Hodgkin’s lymphomas, chronic lymphocytic leukaemias and skin cancers. Br J Cancer 1996, 74:1847–1850.

    PubMed  CAS  Google Scholar 

  9. Matutes E, Wechsler A, Gomez R, et al.: Unusual T-cell phenotype in advanced B-chronic lymphocytic leukaemia. Br J Haematol 1981, 49:635–642.

    PubMed  CAS  Google Scholar 

  10. Kimby E, Mellstedt H, Nilsson B, et al.: Differences in blood T and NK cell populations between chronic lymphocytic leukemia of B cell type (B-CLL) and monoclonal B-lymphocytosis of undetermined significance (B-MLUS). Leukemia 1989, 3:501–504.

    PubMed  CAS  Google Scholar 

  11. Tinhofer I, Marschitz I, Kos M, et al.: Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia. Blood 1998, 91:4273–4281.

    PubMed  CAS  Google Scholar 

  12. Wen T, Mellstedt H, Jondal M: Presence of clonal T cell populations in chronic B lymphocytic leukemia and smoldering myeloma. J Exp Med 1990, 171:659–666.

    Article  PubMed  CAS  Google Scholar 

  13. Alatrakchi N, Farace F, Frau E, et al.: T-cell clonal expansion in patients with B-cell lymphoproliferative disorders. J Immunother 1998, 21:363–370.

    Article  PubMed  CAS  Google Scholar 

  14. Goolsby CL, Kuchnio M, Finn WG, Peterson L: Expansions of clonal and oligoclonal T cells in B-cell chronic lymphocytic leukemia are primarily restricted to the CD3(+)CD8(+) T-cell population. Cytometry 2000, 42:188–195.

    Article  PubMed  CAS  Google Scholar 

  15. Farace F, Orlanducci F, Dietrich PY, et al.: T cell repertoire in patients with B chronic lymphocytic leukemia: evidence for multiple in vivo T cell clonal expansions. J Immunol 1994, 153:4281–4290.

    PubMed  CAS  Google Scholar 

  16. Serrano D, Monteiro J, Allen SL, et al.: Clonal expansion within the CD4+CD57+ and CD8+CD57+ T cell subsets in chronic lymphocytic leukemia. J Immunol 1997, 158:1482–1489.

    PubMed  CAS  Google Scholar 

  17. Rezvany MR, Jeddi-Tehrani M, Osterborg A, et al.: Oligoclonal TCRBV gene usage in B-cell chronic lymphocytic leukemia: major perturbations are preferentially seen within the CD4 T-cell subset. Blood 1999, 94:1063–1069. This study demonstrates oligoclonal in vivo expansion of T cells in patients with CLL.

    PubMed  CAS  Google Scholar 

  18. Frolova EA, Richards SJ, Jones RA, et al.: Immunophenotypic and DNA genotypic analysis of T-cell and NK-cell subpopulations in patients with B-cell chronic lymphocytic leukaemia (B-CLL). Leuk Lymphoma 1995, 16:307–318.

    PubMed  CAS  Google Scholar 

  19. Porakishvili N, Roschupkina T, Kalber T, et al.: Expansion of CD4+ T cells with a cytotoxic phenotype in patients with Bchronic lymphocytic leukaemia (B-CLL). Clin Exp Immunol 2001, 126:29–36.

    Article  PubMed  CAS  Google Scholar 

  20. Dianzani U, Omede P, Marmont F, et al.: Expansion of T cells expressing low CD4 or CD8 levels in B-cell chronic lymphocytic leukemia: correlation with disease status and neoplastic phenotype. Blood 1994, 83:2198–2205.

    PubMed  CAS  Google Scholar 

  21. Rossi E, Matutes E, Morilla R, et al.: Zeta chain and CD28 are poorly expressed on T lymphocytes from chronic lymphocytic leukemia. Leukemia 1996, 10:494–497.

    PubMed  CAS  Google Scholar 

  22. Kneitz C, Goller M, Wilhelm M, et al.: Inhibition of T cell/B cell interaction by B-CLL cells. Leukemia 1999, 13:98–104.

    Article  PubMed  CAS  Google Scholar 

  23. Cantwell M, Hua T, Pappas J, Kipps TJ: Acquired CD40-ligand deficiency in chronic lymphocytic leukemia. Nat Med 1997, 3:984–989.

    Article  PubMed  CAS  Google Scholar 

  24. Lacombe C, Gombert J, Dreyfus B, et al.: Heterogeneity of serum IgG subclass deficiencies in B chronic lymphocytic leukemia. Clin Immunol 1999, 90:128–132.

    Article  PubMed  CAS  Google Scholar 

  25. Lotz M, Ranheim E, Kipps TJ: Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia B cells. J Exp Med 1994, 179:999–1004.

    Article  PubMed  CAS  Google Scholar 

  26. Totterman TH, Carlsson M, Simonsson B, et al.: T-cell activation and subset patterns are altered in B-CLL and correlate with the stage of the disease. Blood 1989, 74:786–792.

    PubMed  CAS  Google Scholar 

  27. Prieto A, Garcia-Suarez J, Reyes E, et al.: Diminished DNA synthesis in T cells from B chronic lymphocytic leukemia after phytohemagglutinin, anti-CD3, and phorbol myristate acetate mitogenic signals. Exp Hematol 1993, 21:1563–1569.

    PubMed  CAS  Google Scholar 

  28. Scrivener S, Kaminski ER, Demaine A, Prentice AG: Analysis of the expression of critical activation/interaction markers on peripheral blood T cells in B-cell chronic lymphocytic leukaemia: evidence of immune dysregulation. Br J Haematol 2001, 112:959–964. This study used immunophenotype to demonstrate that T-cell populations in patients with CLL display a phenotype that reflects dysregulated immune function.

    Article  PubMed  CAS  Google Scholar 

  29. Kay NE: Abnormal T-cell subpopulation function in CLL: excessive suppressor (T gamma) and deficient helper (T mu) activity with respect to B-cell proliferation. Blood 1981, 57:418–420.

    PubMed  CAS  Google Scholar 

  30. Zeya HI, Keku E, Richards F II, Spurr CL: Monocyte and granulocyte defect in chronic lymphocytic leukemia. Am J Pathol 1979, 95:43–53.

    PubMed  CAS  Google Scholar 

  31. Itala M, Vainio O, Remes K: Functional abnormalities in granulocytes predict susceptibility to bacterial infections in chronic lymphocytic leukaemia. Eur J Haematol 1996, 57:46–53.

    Article  PubMed  CAS  Google Scholar 

  32. Itala M, Vanhatalo S, Remes K: Effect of recombinant human granulocyte-macrophage colony-stimulating factor (GMCSF) on chemotherapy-induced myelosuppression in patients with chronic lymphocytic leukemia: a crossover study. Leuk Lymphoma 1997, 25:503–508.

    PubMed  CAS  Google Scholar 

  33. O’Brien S, Kantarjian H, Beran M, et al.: Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia. Leukemia 1997, 11:1631–1635.

    Article  PubMed  CAS  Google Scholar 

  34. Itala M, Pelliniemi TT, Remes K, et al.: Long-term treatment with GM-CSF in patients with chronic lymphocytic leukemia and recurrent neutropenic infections. Leuk Lymphoma 1998, 32:165–174.

    PubMed  CAS  Google Scholar 

  35. de Nully Brown P, Hansen MM: GM-CSF treatment in patients with B-chronic lymphocytic leukemia. Leuk Lymphoma 1999, 32:365–368.

    PubMed  Google Scholar 

  36. Ultmann JE, Fish W, Osserman E, Gellhorn A: The clinical implications of hypogammaglobulinemia in patients with chronic lymphocytic leukemia and lymphocytic lymphosarcoma. Ann Intern Med 1959, 51:501–516.

    PubMed  CAS  Google Scholar 

  37. Shaw R, Szwed C, Boggs D, et al.: Infection and immunity in chronic lymphocytic leukemia. Arch Intern Med 1960, 106:467–478.

    Google Scholar 

  38. Diehl LF, Ketchum LH: Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol 1998, 25:80–97. A comprehensive review of autoimmune complications in patients with CLL. The authors discuss the great paradox of autoimmunity in patients with a disease that is generally considered immunosuppressive.

    PubMed  CAS  Google Scholar 

  39. Davey FR, Kurec AS, Tomar RH, Smith JR: Serum immunoglobulins and lymphocyte subsets in chronic lymphocytic leukemia. Am J Clin Pathol 1987, 87:60–65.

    PubMed  CAS  Google Scholar 

  40. Orfao A, Gonzalez M, San Miguel JF, et al.: Surface phenotype and immunoglobulin levels in B-cell chronic lymphocytic leukaemia. Haematologia 1990, 23:49–56.

    PubMed  CAS  Google Scholar 

  41. Itala M, Helenius H, Nikoskelainen J, Remes K: Infections and serum IgG levels in patients with chronic lymphocytic leukemia. Eur J Haematol 1992, 48:266–270.

    Article  PubMed  CAS  Google Scholar 

  42. Griffiths H, Lea J, Bunch C, et al.: Predictors of infection in chronic lymphocytic leukaemia (CLL). Clin Exp Immunol 1992, 89:374–377.

    Article  PubMed  CAS  Google Scholar 

  43. Molica S, Levato D, Levato L: Infections in chronic lymphocytic leukemia: analysis of incidence as a function of length of follow-up. Haematologica 1993, 78:374–377.

    PubMed  CAS  Google Scholar 

  44. Aittoniemi J, Miettinen A, Laine S, et al.: Opsonising immunoglobulins and mannan-binding lectin in chronic lymphocytic leukemia. Leuk Lymphoma 1999, 34:381–385.

    PubMed  CAS  Google Scholar 

  45. Rozman C, Montserrat E, Vinolas N: Serum immunoglobulins in B-chronic lymphocytic leukemia: natural history and prognostic significance. Cancer 1988, 61:279–283.

    Article  PubMed  CAS  Google Scholar 

  46. Copson ER, Ellis BA, Westwood NB, Majumdar G: IgG subclass levels in patients with B cell chronic lymphocytic leukaemia. Leuk Lymphoma 1994, 14:471–473.

    PubMed  CAS  Google Scholar 

  47. Chapel HM, Lee M: Immunoglobulin replacement in patients with chronic lymphocytic leukemia (CLL): kinetics of immunoglobulin metabolism. J Clin Immunol 1992, 12:17–20.

    Article  PubMed  CAS  Google Scholar 

  48. Kurec AS, Davey FR: Impaired synthesis of immunoglobulin in patients with chronic lymphocytic leukemia. Am J Hematol 1987, 25:131–142.

    Article  PubMed  CAS  Google Scholar 

  49. Apostolopoulos A, Symeonidis A, Zoumbos N: Prognostic significance of immune function parameters in patients with chronic lymphocytic leukaemia. Eur J Haematol 1990, 44:39–44.

    Article  PubMed  CAS  Google Scholar 

  50. Kunicka J, Platsoucas CD: Leukaemic B cells from patients with chronic lymphocytic leukaemia suppress immunoglobulin production by lymphocytes from normal donors. Scand J Immunol 1988, 28:1–10.

    Article  PubMed  CAS  Google Scholar 

  51. Fernandez LA, MacSween JM, Langley GR: Immunoglobulin secretory function of B cells from untreated patients with chronic lymphocytic leukemia and hypogammaglobulinemia: role of T cells. Blood 1983, 62:767–774.

    PubMed  CAS  Google Scholar 

  52. Kay NE, Perri RT: Evidence that large granular lymphocytes from B-CLL patients with hypogammaglobulinemia downregulate B-cell immunoglobulin synthesis. Blood 1989, 73:1016–1019.

    PubMed  CAS  Google Scholar 

  53. Perri RT, Kay NE: Large granular lymphocytes from B-chronic lymphocytic leukemia patients inhibit normal B cell proliferation. Am J Hematol 1989, 31:166–172.

    Article  PubMed  CAS  Google Scholar 

  54. Fust G, Czink E, Minh D, et al.: Depressed classical complement pathway activities in chronic lymphocytic leukaemia. Clin Exp Immunol 1985, 60:489–495.

    PubMed  CAS  Google Scholar 

  55. Heath ME Cheson BD: Defective complement activity in chronic lymphocytic leukemia. Am J Hematol 1985, 19:63–73.

    Article  PubMed  CAS  Google Scholar 

  56. Schlesinger M, Broman I, Lugassy G: The complement system is defective in chronic lymphatic leukemia patients and in their healthy relatives. Leukemia 1996, 10:1509–1513.

    PubMed  CAS  Google Scholar 

  57. Miszlai Z, Czink E, Varga L, et al.: Repressed classical complement pathway activities and clinical correlations in chronic lymphocytic leukaemia. Acta Med Hung 1986, 43:389–395.

    PubMed  CAS  Google Scholar 

  58. Ross SC, Densen P: Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency. Medicine 1984, 63:243–273.

    Article  PubMed  CAS  Google Scholar 

  59. Rai KR, Peterson BL, Appelbaum FR, et al.: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000, 343:1750–1757.

    Article  PubMed  CAS  Google Scholar 

  60. Leporrier M, Chevret S, Cazin B, et al.: Randomized comparison of fludarabine, CAP, and CHOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001, 98:2319–2325.

    Article  PubMed  CAS  Google Scholar 

  61. Cheson BD: Infectious and immunosuppressive complications of purine analog therapy. J Clin Oncol 1995, 13:2431–2448.

    PubMed  CAS  Google Scholar 

  62. Perkins JG, Flynn JM, Howard RS, Byrd JC: Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer 2002, 94:2033–2039. This is a report of infections experienced by patients with CLL who are refractory to fludarabine. This group of patients is at the greatest risk for morbidity and mortality from infection.

    Article  PubMed  Google Scholar 

  63. Byrd JC, Hargis JB, Kester KE, et al.: Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for Pneumocystis carinii pneumonia prophylaxis. Am J Hematol 1995, 49:135–142.

    Article  PubMed  CAS  Google Scholar 

  64. Sudhoff T, Arning M, Schneider W: Prophylactic strategies to meet infectious complications in fludarabine-treated CLL. Leukemia 1997, 11(Suppl 2):S38-S41.

    PubMed  Google Scholar 

  65. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia: a randomized, controlled clinical trial. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. N Engl J Med 1988, 319:902–907. This randomized study evaluated the efficacy of IVIG in patients with CLL at risk for infection.

  66. Bunch C: Immunoglobulin replacement in chronic lymphocytic leukaemia. Nouv Rev Fr Hematol 1988, 30:419–422.

    PubMed  CAS  Google Scholar 

  67. Griffiths H, Brennan V, Lea J, et al.: Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors. Blood 1989, 73:366–368.

    PubMed  CAS  Google Scholar 

  68. Chapel H, Griffiths H, Brennan V, et al.: Hypogammaglobulinaemia in low grade B cell tumours; significance and therapy. Immunol Invest 1991, 20:187–191.

    PubMed  CAS  Google Scholar 

  69. Gamm H, Huber C, Chapel H, et al.: Intravenous immune globulin in chronic lymphocytic leukaemia. Clin Exp Immunol 1994, 97(Suppl 1):17–20.

    PubMed  Google Scholar 

  70. Jurlander J, Geisler CH, Hansen MM: Treatment of hypogammaglobulinaemia in chronic lymphocytic leukaemia by lowdose intravenous gammaglobulin. Eur J Haematol 1994, 53:114–118.

    Article  PubMed  CAS  Google Scholar 

  71. Boughton BJ, Jackson N, Lim S, Smith N: Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemia. Clin Lab Haematol 1995, 17:75–80.

    Article  PubMed  CAS  Google Scholar 

  72. Molica S, Musto P, Chiurazzi F, et al.: Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study. Haematologica 1996, 81:121–126.

    PubMed  CAS  Google Scholar 

  73. Gribabis DA, Panayiotidis P, Boussiotis VA, et al.: Influenza virus vaccine in B-cell chronic lymphocytic leukaemia patients. Acta Haematol 1994, 91:115–118.

    Article  PubMed  CAS  Google Scholar 

  74. Hartkamp A, Mulder AH, Rijkers GT, et al.: Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia. Vaccine 2001, 19:1671–1677.

    Article  PubMed  CAS  Google Scholar 

  75. Sinsalo M, Aittoniemi J, Kayhty H, Vilpo J: Haemophilus influenzae type b (Hib) antibody concentrations and vaccination responses in patients with chronic lymphocytic leukaemia: predicting factors for response. Leuk Lymphoma 2002, 43:1967–1969.

    Article  PubMed  Google Scholar 

  76. Sinisalo M, Aittoniemi J, Oivanen P, et al.: Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia. Br J Haematol 2001, 114:107–110.

    Article  PubMed  CAS  Google Scholar 

  77. Rapezzi D, Sticchi L, Racchi O, et al.: Influenza vaccine in chronic lymphoproliferative disorders and multiple myeloma. Eur J Haematol 2003, 70:225–230.

    Article  PubMed  Google Scholar 

  78. Jurlander J, de Nully Brown P, Skov PS, et al.: Improved vaccination response during ranitidine treatment, and increased plasma histamine concentrations, in patients with B cell chronic lymphocytic leukemia. Leukemia 1995, 9:1902–1909.

    PubMed  CAS  Google Scholar 

  79. Sinisalo M, Aittoniemi J, Kayhty H, Vilpo J: Vaccination against infections in chronic lymphocytic leukemia. Leuk Lymphoma 2003, 44:649–652. An excellent review of vaccine strategies against microorganisms and their results for patients with CLL.

    Article  PubMed  CAS  Google Scholar 

  80. Bonyhadi M, Leis JF, Grosmaire L, et al.: Autologous T cell therapy for B-CLL [abstract]. Blood 2002, 100:774. This very recent report details the "Xcellerate" process for ex vivo Tcell expansion. The functional characteristics of "Xcellerated" T cells are also described. This technology holds promise for immune reconstitution as well as potential for treatment of the disease itself.

    Article  CAS  Google Scholar 

  81. Rassam SMB, Jabbar SAB: T cell expansion in chronic lymphocytic leukaemia (CLL) using CD3/CD28 co-stimulation and feeder cells: differing patterns and preferential CD4 expansion [abstract]. J Clin Oncol 2003, 22:581.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, 77030, Houston, TX, USA

    William G. Wierda MD, PhD

Authors
  1. William G. Wierda MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wierda, W.G. Immunologic monitoring in chronic lymphocytic leukemia. Curr Oncol Rep 5, 419–425 (2003). https://doi.org/10.1007/s11912-003-0029-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11912-003-0029-3

Keywords

Search

Navigation